Evidence map›Paper›PMID 33275723›Full record

ReviewHematology. American Society of Hematology. Education Program2020

Immunotherapy with cells.

Elise A Chong, David L Porter

Open access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Elise A ChongLymphoma Program and Cell Therapy and Transplant Program, Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
David L PorterLymphoma Program and Cell Therapy and Transplant Program, Hematology-Oncology Division, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
University of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both older and newer cell therapies have demonstrated impressive responses in otherwise poor-prognosis lymphomas. Consequently, cellular therapy now plays a major role in the management of many non-Hodgkin lymphomas. In this article, we examine the role of chimeric antigen receptor (CAR) T cells, allogeneic stem cell transplantation, and virus-directed T cells for treatment of lymphomas. We review the current indications for CAR T cells and discuss our clinical approach to selecting and treating patients with aggressive B-cell lymphomas to receive CD19-directed CAR T cells. In addition, we highlight newer cell therapies and provide an overview of promising future approaches that have the potential to transform immunotherapy with cells to treat lymphomas.

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansLymphoma, Large B-Cell, DiffuseMiddle AgedPrednisoneReceptors, Chimeric AntigenRituximabVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolReceptors, Chimeric AntigenRituximabVincristine

Identifiers

PMID33275723
PMCPMC7727576
OpenAlexW3110336770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.